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Copyright © 2008 AHC The successful treatment of breast cancer is dependent upon a number of complex factors.
Her-2/neu gene amplification is known to be one of the most common genetic alterations
associated with breast cancer and its accurate determination has become necessary for the
selection of patients for trastuzumab therapy.
The aim of this study was to prove the consistency of chromogenic in situ hybridisation
(CISH) technique after analyzing the overexpression of the Her-2/neu proto-oncogene in 100
invasive breast carcinomas and by comparing CISH results with immunohistochemistry
(IHC) and fluorescence in situ hybridisation (FISH). Moreover, it was done to evaluate the
possible correlation of estrogen (ERs) and progesterone receptors (PRs), the proliferation
marker Ki67 and the tumour suppressor gene p53 with HER-2/neu status of these breast
carcinomas.
Of the 100 breast carcinomas that were analysed, 22 cases showed HER-2/neu amplifica-
tion, 66 cases showed no amplification, whereas 12 cases were non-interpretable in both
assays (FISH and CISH). Consequently, the overall concordance between FISH and CISH
was 100%. Additionally, it was observed that when HER-2/neu gene was overexpressed,
there was an association with negative PRs and ERs status, negative p53 protein expression
and high Ki67 labelling index.
It is concluded that patients with tumours scoring 2+ with the CBE356 antibody (borderline
immunohistochemistry-tested cases) would also benefit from CISH as it is shown to be high-
ly accurate, practical and can be easily integrated into routine testing in any histopathology
laboratory. Finally, CISH represents an important addition to the HER2 testing algorithm.
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I. Introduction
Transmembrane receptors play a major role in regulat-
ing cellular proliferation, differentiation, cell migration and
cellular death. Changes in the structure and the expression
of the genes that encode those receptors result in signal
transduction disorders and contribute to tumorigenesis
[20]. The oncogene HER-2/c-erbB-2 encodes a transmem-
brane tyrosine kinase growth factor receptor that belongs
to the EGFR/HER family, which is comprised of 4 proteins
known as HER-1/c-erbB-1, HER-2/c-erbB-2, HER-3/c-
erbB-3, and HER-4/c-erbB-4. C-erbB-2 participates in a
network of signalling when homodimerised or dimerised
with other members of the erbB protein family. Amplifica-
tion of the gene leads to amplified transcriptive activity,
tumorigenesis and tumour metastasis.
Amplification or overexpression of HER-2/neu is seenPothos et al. 60
in approximately 30% of invasive breast cancers and studies
have shown that HER-2/neu overexpression is an adverse
prognostic factor in patients with node positive disease [17].
HER-2/neu overexpression has been reported to be associ-
ated with positive lymph nodes, high histologic grade, high
proliferation rate, lack of expression of estrogen and proges-
terone receptors, and shorter survival rates. There is also
fairly consistent evidence that HER-2/neu overexpression is
predictive of sensitivity to anthracyclines [5]. Additionally,
HER-2/neu represents an ideal therapeutic target because it
is accessible as a cell surface receptor and is expressed at
high levels in breast tumours. A monoclonal antibody,
known as trastuzumab, has been shown to be effective as a
single agent in the treatment of patients with metastatic
breast cancer, who failed to respond to treatment with
chemotherapy [3]. Moreover, Herceptin® plus chemotherapy
has been shown to be more effective than chemotherapy
alone as first-line therapy in the metastatic setting [21]. The
accurate testing of Her-2/neu by FISH ensures that costly
and potentially toxic trastuzumab treatment will not be given
to patients with no amplification of HER-2/neu proto-
oncogene.
The aim of the present study was to validate whether
CISH is a practical alternative technique to FISH for assess-
ing HER-2/neu gene amplification in negative, positive and
borderline immunohistochemistry-tested cases. The results
were compared with FISH testing carried out on a series of
the same 100 cases of breast carcinoma. Finally, it evaluated
the possible correlation of ERs and PRs, the proliferation
marker Ki67 and the tumour suppressor gene p53 with HER-
2/neu status.
II. Materials and Methods
Patients
One hundred cases of invasive ductal breast carcinomas
diagnosed between 2001 and 2007 were randomly selected
from the pathology department of Helena Venizelou Hospi-
tal, Athens, Greece. The age of the women ranged from 34
to 80 years (mean age 59.2 years).
Immunohistochemistry
Immunohistochemical stainings were performed on 4
µm thick tumour sections after microwave antigen retrieval
(0.01 M citrate buffer, pH 6.0 for 15 min) using the commer-
cially available monoclonal antibodies to ER (1D5, 1:100
dilution; DAKO), PR (1A6, 1:20 dilution; Biogenex, San
Ramon, CA), external domain of HER-2/neu (CBE356
mouse monoclonal antibody, clone 10A7, 1:200 dilution;
Novocastra, Newcastle upon Tyne, UK), p53 (DO7, 1:50
dilution; DAKO), and Ki67 (MIB-1, 1:80 dilution; DAKO).
The staining for ER, PR, and p53 was classified as pos-
itive if more than 10% of the tumour cells exhibited nuclear
overexpression and the proliferation index was determined
by exactly measuring the percentage of Ki67 immunostained
nuclei using the CAS 200 image analyzer.
Evaluation of HER-2/neu immunohistochemical ex-
pression was performed by semiquantitative scoring by BD
(based on the scoring guidelines of DAKO) as follows:
Score 0: no staining or membrane staining in <10% of
tumour cells; Score 1+: faint membrane staining in >10%
of tumour cells; Score 2+: weak—moderate complete
membrane staining in >10% of tumour cells and 3+:
strong, complete membrane staining in >10% of tumour
cells. Scores of 0 and 1+ were considered as negative for
HER-2/neu expression, 3+ as immunopositive, while 2+
were weakly or borderline positive.
Fluorescence in situ hybridisation
Paraffin-embedded tissue sections (4 µm thick) were
analysed using FISH protocol (Vysis, Downers Grove, IL).
The slides were deparaffinised in fresh xylene (3×, 5 min
each), dehydrated in absolute ethanol and air dried. After
several washes in 2×SSC, the tissue sections were incubated
in 1 M NaSCN (pre-treatment reagent) at 80°C for 30 min.
Cytoplasm surrounding the interphase nuclei was removed
by protease digestion (protease solution) at 37°C for 10 min,
increasing the accessibility of the probes to the targeted se-
quences and decreasing any background signals. The slides
were then rinsed in dH2O for 5 min and allowed to air dry.
The hybridisation mixture (including a centomere 17-
specific, SpectrumGreen-labelled DNA probe and a HER-2/
neu-specific, SpectrumOrange-labelled DNA probe) was
applied to the pre-treated slides, a coverslip was added and
the edges of the hybridisation area were sealed with rubber
cement. To allow hybridisation, the slides were incubated
for 16–24 hr in a humidified chamber at 37°C. After hybrid-
isation, the slides were washed twice for 5 min each time in
0.05×SSC at 42°C. The slides were then rinsed in 2×SSC/
0.3% NP-40 and embedded in mounting medium containing
DAPI (0.5 µg/ml, Vysis) for nuclear counterstaining.
The slides were stored at –20°C until enumerated using
Zeiss-Axioscope fluorescence microscope. At least 60 cells
were scored in each slide and the copy numbers of HER-2/
neu and CEP17 for each cell were recorded. HER-2/neu was
quantified using the ratio of HER-2/neu to CEP17 signal
counts. HER2/CEP17 ratio greater than 2 was interpreted as
positive for gene amplification. Polysomy of chromosome
17 was defined as the presence of three or more CEP17
signals in >6% of the tumour cells evaluated.
Chromogenic in situ hybridisation
CISH was performed on 4 µm thick archived formalin-
fixed paraffin-embedded tumour samples. Sections were de-
paraffinised 3× in fresh xylene for 5 min each, dehydrated in
two changes of absolute ethanol for 5 min each and allowed
to air dry. The slides were then incubated in pretreatment
buffer (1 M sodium isothiocyanate; Vysis) for 13 min at
80°C, and were immediately washed with deionised water
for 2 min. Enzymatic digestion was performed by incubating
sections with protease (Vysis) for 2 min at 37°C. The slides
were then washed with deionised water, dehydrated with a
graded series of ethanol and air-dried. Fifteen microlitres of
digoxigenin-labelled HER-2/neu probe (Zymed, South SanCISH vs FISH and IHC for Her-2/neu Assessment in Breast Cancer 61
Francisco, CA, USA) were applied to the sections and the
slides were denatured at 74°C for 5 min. After overnight hy-
bridisation at 37°C, the slides were washed in 2×SSC/0.3%
NP-40 (Vysis) at 73°C for 2 min, followed by three washes
in distilled water. Then, the sections were blocked with 3%
H2O2 in absolute methanol and incubated with a blocking re-
agent for 10 min at an ambient temperature. The hybridisa-
tion signals were detected after sequential incubations with
mouse anti-DIG (60 min at room temperature), polymerised
HRP (horseradish peroxidase) anti-mouse antibody (60 min
at RT) and 3-3-diaminobenzedine (DAB), according to the
manufacturer’s instructions (Zymed). The sections were
counterstained with hematoxylin.
The CISH hybridisations were evaluated using light
microscope under a 40× objective. Unaltered gene copy
number was defined as one to five signals per nucleus (veri-
fy chromosome 17 aneuploidy in cases with 3–5 copies of
HER-2/neu gene/nucleus). Low level amplification was de-
fined as 6 to 10 signals per nucleus or small gene clusters in
more than 50% of tumour cells (verify true HER-2/neu
amplification with absence of chromosome 17 aneuploidy).
High level amplification of HER-2/neu was defined as
numerous (>10) signals per nucleus or large gene clusters
in more than 50% of tumour cells. It should be also noted
that both low and high levels of amplification of the HER-
2/neu was regarded as amplification-positive.
III. Results
HER-2/neu by IHC and correlation of IHC and FISH results
A total of 100 samples of invasive ductal breast carci-
noma were analysed. HER-2/neu staining by IHC was
graded as HER-2/neu negative (score 0 and 1+) in 55
tumours, 14 tumours had equivocal Her-2/neu status (2+)
and 31 tumours were HER-2/neu positive (3+).
Of the 100 breast carcinomas, it was also observed that
when HER-2/neu gene was overexpressed, there was an as-
sociation with negative progesterone and estrogen receptor
status, negative p53 protein expression and high Ki67 label-
ling index, although these correlations were not statistically
significant (data not shown).
The correlation of IHC and FISH results of the 100
samples is presented in Table 1, where 12 cases were non-
interpretable, due to high background and low signal inten-
sity. Moreover, one negative case of 50, none of the 11 cases
graded as 2+ and 21 out of the 27 3+ cases have shown gene
amplification by FISH.
HER-2/neu by CISH and FISH
After CISH assay, 69 cases showed no gene amplifica-
tion, whereas one of the 52 0/1+ cases, none of the 12 2+ and
21 of the 27 3+ were HER-2/neu gene amplified. The one
case interpreted as 1+ (CISH positive) showed low-level
gene amplification, whereas of the 21 cases interpreted as 3+
(CISH positive), 1 showed low-level gene amplification and
20 showed high-level gene amplification. Nine samples
were not interpretable by CISH (Table 2). Of the 100 cases
with invasive ductal breast carcinoma, which were analysed,
88 were assessable for FISH and CISH, 9 cases were not
successful in either technique and 3 showed HER-2/neu
non-amplification by CISH, while on FISH assay no hybrid-
isation signals were detected. Of the 88 breast carcinoma,
22 cases showed HER-2/neu amplification in both assays,
whereas 66 cases showed no amplification (Table 3). The
overall concordance between FISH and CISH was 100%.
Tumour specimens showing HER-2/neu amplification and
non-amplification by FISH and CISH are shown in
Figures 1 and 2.
IV. Discussion
The accurate and rapid determination of HER-2/neu
amplification has become necessary for the prognostic eval-
uation and selection of patients, who are candidates for treat-
ment with Herceptin® that has been shown to significantly
prolong survival in HER-2/neu positive breast carcinoma. In
routine clinical practice, immunohistochemical study and
fluorescence in situ hybridisation are used to evaluate the
Table 1. Comparison between HER-2/neu amplification by FISH
and overexpression by IHC/CBE356
* CBE356: mouse monoclonal antibody, clone 10A7 (Novocastra,





0/1+ 49 1 5
2+ 11 0 3
3+ 62 1 4
Table 2. Comparison between HER-2/neu amplification by CISH
and overexpression by IHC/CBE356
* This case (1) was low-level gene amplified.
† One case (1/21) was low-level amplified, whereas 20/21 cases





0/1+ 51 1* 3
2+ 12 0 2
3+ 6 21† 4




Non-amplification 66 (75.0%) 0
Amplification 0 22 (25.0%)Pothos et al. 62
HER-2/neu status as both of them have been FDA-approved.
Although IHC and FISH should yield similar results because
HER-2/neu overexpression results from gene amplification,
there are discrepancies between IHC and FISH results.
There are several studies comparing IHC and FISH in
paraffin embedded tissues and the concordance is reported
to be from 73% to 98% [9, 14, 16, 25].
Immunohistochemical staining can be significantly
affected by technical issues (tissue fixation) and interpreta-
tion can be problematic, particularly in cases with low-level
amplification, as there is subjectivity in grading, since there
are no available quantitative computer-assisted imaging
techniques. Furthermore, a number of commercially avail-
able antibodies have shown differences in specificities and
sensitivities and identify different c-erbB2 protein domains
[1, 10, 12, 15, 19, 23, 26]. The present study tested the
CBE356 mouse monoclonal antibody, clone 10A7, that
showed strong positive membrane staining compared to
CB11 that is prone to heavy background. Moreover, IHC
staining of HER-2/neu with CBE356 has proved to be sig-
nificantly cheaper than HercepTest. However, Gancberg et
al. and Tubbs et al. have shown discordance between gene
amplification and the detection of protein amplification
by immunohistochemistry [7, 24]. In these cases, in order
to avoid false-positive cases, it has been suggested to per-
form FISH in 2+ and 3+ IHC staining tumours. Nevertheless,
the significant cardiotoxicity of trastuzumab emphasises
the need of accurate assessment of HER-2/neu status.
An alternative method to FISH, called CISH, has been
introduced and validated that allows detection of HER-2/neu
gene copies by using a simple immunohistochemistry-like
peroxidase reaction, enumeration of gene copy number with
simultaneous histologic examination by regular bright-field
microscopy and permanent storage as the CISH signal inten-
sity that does not diminish over time. Moreover, the most
difficult category in CISH is the low-level amplification (6
to 10 gene copies/cell), in which accurate enumeration of the
gene copies is necessary, as in routine diagnostic enumera-
tion of gene copies exceeding 10 is not needed. However,
even in these cases the microscopic evaluation is much
faster than that of FISH.
In addition, in the present study, as the HER2 CISH
(Zymed) is based on single colour detection, approximately
half of the nonamplified tumours showed one to two signals
per cell, and half showed three to five copies/nucleus. The
latter is because of chromosomal aneuploidy and should be
Fig. 1. CISH detection of HER-2/neu oncogene in invasive breast carcinomas. (A) A tumour with one to two clearly identifiable copies of HER-
2/neu oncogene (no amplification). (B) A typical HER-2/neu amplification appeared either as a peroxidase positive cluster of gene copies, or as
multiple individual gene copies (C). Counterstained with haematoxylin.
Fig. 2. FISH detection of HER-2/neu oncogene in invasive breast carcinomas. (A) Non-amplified tumour. The HER-2/neu gene signal is red and
chromosome 17 centromere is green. (B) High level HER2 gene amplification as the HER2/CEP17 ratio is greater than 2. (C) Low level HER2
gene amplification.CISH vs FISH and IHC for Her-2/neu Assessment in Breast Cancer 63
regarded as no HER-2/neu amplification, which is due to
DNA replication during S and G2/M phases of the cell cycle.
Also, a small proportion (10% to 30%) of aneuploid cancer
cells may contain five to eight signals/nucleus (polysomic
cases); this should also be interpreted as a negative finding
(no HER-2/neu amplification). The theoretical advantage of
Vysis’ two-colour FISH is its ability to distinguish chromo-
somal amplification from aneuploidy using a differentially
labelled reference probe (chromosome 17 centromere). How-
ever, as yet there are no large comparisons between Vysis’
two-colour FISH and the CISH-like single-colour FISH,
which could confirm the advantage of the two-colour sys-
tem. On the other hand, a recent study by Elkin et al. demon-
strated that it is more cost-effective to use FISH alone or as
a confirmation of all positive HercepTest results, than to
use FISH to confirm only weakly positive (2+) results or
HercepTest alone [6].
In the current study, after analysing one hundred cases
of invasive ductal breast carcinomas, a high level of concor-
dance between CISH and FISH (100%) was observed. This
was also found by several other studies [4, 8, 22, 26]. The
complete agreement of FISH and CISH results points out
that the chromogenic ISH technique seems to be sensitive
and specific for detection of HER-2/neu amplification in
human archival tumour samples and could potentially fulfill
the same role as FISH in the HER2 testing algorithm. As can
also be seen from our results, the present study includes a
false positive rate (as detected by FISH) of 19.3% (i.e. 6/31
cases, Tables 1 and 2) for the CBE356 3+ cases. The number
of discrepancies was similar if CISH was used instead of
FISH and the current literature suggests a 10–16% false-
positive rate for these patients that may be due to the sub-
jective score interpretation of IHC [2, 18, 24]. In view of the
clinical consequences, this would subject these patients to
an unnecessary Herceptin® treatment without any benefit
while importantly they would be exposed to the risk of
cardiac toxicity. Based on this, it is suggested to apply the
HER2 testing algorithm to all positive IHC scored cases to
elucidate their gene amplification status.
Furthermore, it was noted that a total of 12 cases were
non-interpretable by either FISH or CISH. This was due to
truncated nuclei, which were small in diameter and should
not be scored. Additionally, in some cases, nuclei that were
not intact were observed; these contained central unstained
areas and should not be evaluated as a missing area which
may have contained signals that cannot be assessed.
Additionally, in the current study, it was found that
when HER-2/neu was overexpressed, there was a tendency
(not statistically significant) for negative estrogen and
progesterone receptor status and in those cases there was
also a high proliferative activity (Ki67) and p53 protein
expression. Similar data has been reported elsewhere and
these findings negate the widely held belief that ER and PR
positive tumours are rarely HER2 positive [11, 13].
Although a further number of cases would allow un-
biased assessment of sensitivity and specificity of CISH
versus FISH, the superiority of one HER-2/neu test over
another can best be solved, in a future study, by using the
clinical response to trastuzumab therapy as reference. Con-
clusively, the concordance of CISH with FISH in this study
is especially encouraging and it was shown that CISH is
an appealing alternative to FISH and that the combined
use of IHC and CISH can be considered, even though the
recommendations of the College of American Pathologists
regarding HER2 testing in breast cancer and UK guidelines
dictate FISH assay alone to analyse cases for which IHC
results are inconclusive (borderline 2+ cases).
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